Milestone Pharmaceuticals Inc. is a private venture capital-funded cardiovascular drug development company developing novel small molecule therapeutics for transient cardiovascular conditions. The company’s lead product, etripamil (MSP-2017), is entering Phase 3 development. Etripamil is a potent and short-acting nasally-delivered calcium channel antagonist in development for the episodic treatment of paroxysmal supraventricular tachycardia (PSVT).
Milestone Pharmaceuticals Announces $80 Million Private Financing
Milestone Pharmaceuticals, a late-stage biopharmaceutical company developing interventions for tachycardias, today announced the completion of an $80 million private financing. The equity financing included the support of new and existing institutional investors.